Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions
2026 · 1st Quarter (Jan 1 - Mar 31)
ORCHARD THERAPEUTICS NORTH AMERICA
Filed by ORCHARD THERAPEUTICS NORTH AMERICA.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 18, 2026
- Income
- Not reported
- Expenses
- $350,000.00
- Registrant
- ORCHARD THERAPEUTICS NORTH AMERICA
- Filing UUID
- a73a1115-7270-45ca-be9c-0cf3b164d40b
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's
Literal federal measure citations: H.R. 7871
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.